The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program

By sjmartinez • April 27, 2025

Hanauer SB, Torres EA, Aragon-Han P, Chapman JC, Swaminath AC, Arai R, Butnariu M, Lee TC, Rabizadeh S, Check M, Barrett TA, Hashash JG, Meister T, Yen EF, Kinnucan J, Stein DJ, Ziring D, Shaposhnikov R, Sinh P, Qazi TM, Yarur AJ, Monzur F, Dervieux T, Abraham BP. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics. 2025 Mar 27;17(4):428. doi: 10.3390/pharmaceutics17040428. PMID: 40284422; PMCID: PMC12030419.

Tags: adalimumab, Cedars Sinai DoM, clearance, Digestive Diseases, dose optimization, inflammatory bowel disease, pharmacokinetics; precision medicine, precision-guided dosing, Publications, real-world data, therapeutic drug monitoring

Disparities in Health Care Seeking and Physician Diagnosis of Irritable Bowel Syndrome: Results From a United States Survey

Almario CV, Liu J, Higgins C, Yerneni N, Boules M, Chey WD, Chang L. Disparities in Health Care Seeking and Physician Diagnosis of Irritable Bowel[...]

Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer

Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata[...]

Artificial intelligence-derived splenic response in cardiac positron emission tomography is associated with major adverse cardiovascular events: a multi-site study

Ramirez G, Dharmavaram NL, Shanbhag A, Miller RJH, Kavanagh PB, Yi J, Lemley M, Builoff V, Marcinkiewicz A, Dey D, Hainer J, Wopperer S, Knight[...]